REGN Weekly Options Trade Plan 2025-05-26
Join our Discord channel for live trading signals and discussions:
REGN Weekly Analysis Summary (2025-05-26)
Summary of Each Model’s Key Points Grok/xAI: Moderately bullish on REGN based on short-term momentum above the 10-period EMA, bullish MACD divergence, and positive drug news. Recommends buying the $590 call at ~$12.70 with a profit target of $16.00 and stop at $11.00. Confidence 65%. Claude/Anthropic: Moderately bearish due to breakdown below moving averages, rising VIX, and max pain at $550. Suggests buying the $580 put at $6.60, targeting 50–100% gain and stopping at 25% loss. Confidence 72%. Llama/Meta: Moderately bearish overall but mixed signals on daily vs. 5-minute charts. Proposes a $582.50 put at $9.50, targeting 20% gain and stop at $7.00. Confidence 70%. DeepSeek: Neutral/unclear outlook; technicals mixed and max pain too distant. No trade recommended. Confidence 45%. Gemini/Google: Moderately bearish driven by short-term technicals, rising VIX, and max pain theory. Recommends buying the $565 put (weekly) around mid $2.70–$3.20, with tight risk management. Confidence 65%. Areas of Agreement and Disagreement Agreement: Three of five models tilt bearish (Claude, Llama, Gemini). Rising VIX and max pain at $550 reinforce bearish bias. All note mixed or neutral RSI readings and elevated volatility. Disagreement: Grok/xAI calls for a bullish play on $590 calls. DeepSeek finds no clear edge and avoids a trade. Strike selection and premium tolerance vary among bearish models ($565 vs. $580 vs. $582.50). Conclusion Overall Market Direction Consensus: Moderately Bearish Recommended Trade: Buy a single-leg naked put on REGN’s weekly expiry. • Strike: $580 puts expiring 2025-05-30 • Premium: Target entry at $6.60 (midpoint of $4.80–$8.40 quote) • Size: 1 contract • Expiration: Weekly (2025-05-30) • Entry Timing: At open • Profit Target: $9.90 (50% gain) • Stop-Loss: $4.95 (25% loss) Confidence Level: 70% Key Risks and Considerations: • Wide bid-ask spreads in pre-open; execution risk • Potential upside surprise from drug news or broader market rally • Rapid time decay late in the week if the bearish move stalls